Literature DB >> 12079303

Loss of expression and altered localization of KAI1 and CD9 protein are associated with epithelial ovarian cancer progression.

Christopher D Houle1, Xiao-Yu Ding, Julie F Foley, Cynthia A Afshari, J Carl Barrett, Barbara J Davis.   

Abstract

OBJECTIVE: Impairment of cell adhesion plays a vital role in tumor progression. E- and N-cadherin, CD9, and KAI1 are all adhesion molecules that have been implicated in the progression of several different tumor types. To help explain the potential role these adhesion molecules have in ovarian cancer, comparisons were made between expression patterns in normal ovary and various grades of primary and metastatic epithelial ovarian cancers.
METHODS: Thirty-two primary and 8 metastatic human ovarian epithelial carcinomas and 18 samples of normal ovarian tissue were examined for adhesion molecule expression using immunohistochemistry.
RESULTS: KAI1 and CD9 revealed an inverse relationship between tumor grade and expression levels, characterized by high expression in low-grade tumors and low expression in high-grade tumors and metastases. KAI1 and CD9 also demonstrated a shift in cellular localization from the membrane in grade 1 tumors to the cytoplasm in grade 3 tumors. N-cadherin expression showed a positive trend between expression levels and tumor grade. E-cadherin expression varied little between different tumor grades and metastases. Inclusion cysts (n = 6) and surface invaginations often strongly expressed KAI1, CD9, and E-cadherin. KAI1 expression was variable in ovarian follicles and corpora lutea depending on their stage of development.
CONCLUSIONS: Although sample size is limited, these findings suggest that progression of ovarian epithelial carcinomas is associated with down-regulation and altered cellular localization of KAI1 and CD9. In addition, variable KAI1 expression during follicular and luteal development suggests that it has a physiological function in the ovary. Further investigation will be needed to see if it is also regulated this way during progression of ovarian cancers. (c) 2002 Elsevier Science (USA).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12079303     DOI: 10.1006/gyno.2002.6729

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  27 in total

Review 1.  Tetraspanins and tumor progression.

Authors:  Mekel M Richardson; Lisa K Jennings; Xin A Zhang
Journal:  Clin Exp Metastasis       Date:  2010-12-24       Impact factor: 5.150

2.  Identification of candidate biomarkers for epithelial ovarian cancer metastasis using microarray data.

Authors:  Su Li; Hua Li; Ying Xu; Xiaomei Lv
Journal:  Oncol Lett       Date:  2017-08-02       Impact factor: 2.967

3.  Down-regulation of CD9 expression and its correlation to tumor progression in B lymphomas.

Authors:  Sun-Ok Yoon; Xin Zhang; Arnold S Freedman; David Zahrieh; Izidore S Lossos; Li Li; Yong Sung Choi
Journal:  Am J Pathol       Date:  2010-06-21       Impact factor: 4.307

Review 4.  Novel CD9-targeted therapies in gastric cancer.

Authors:  Yoko Murayama; Kenji Oritani; Shusaku Tsutsui
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

5.  Tetraspanin CD82 Organizes Dectin-1 into Signaling Domains to Mediate Cellular Responses to Candida albicans.

Authors:  Jenny M Tam; Jennifer L Reedy; Daniel P Lukason; Sunnie G Kuna; Mridu Acharya; Nida S Khan; Paige E Negoro; Shuying Xu; Rebecca A Ward; Michael B Feldman; Richard A Dutko; Jane B Jeffery; Anna Sokolovska; Carl N Wivagg; Kara G Lassen; François Le Naour; Vasiliki Matzaraki; Ethan C Garner; Ramnik J Xavier; Vinod Kumar; Frank L van de Veerdonk; Mihai G Netea; Cindy K Miranti; Michael K Mansour; Jatin M Vyas
Journal:  J Immunol       Date:  2019-04-22       Impact factor: 5.422

6.  Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary.

Authors:  Dirk Bauerschlag; Karen Bräutigam; Roland Moll; Jalid Sehouli; Alexander Mustea; Darius Salehin; Maryla Krajewska; John C Reed; Nicolai Maass; Garret M Hampton; Ivo Meinhold-Heerlein
Journal:  J Cancer Res Clin Oncol       Date:  2012-10-23       Impact factor: 4.553

7.  Effects of KAI1 gene on growth and invasion of human hepatocellular carcinoma MHCC97-H cells.

Authors:  Sui-Hai Si; Jian-Min Yang; Zhi-Hong Peng; Yuan-Hui Luo; Ping Zhou
Journal:  World J Gastroenterol       Date:  2004-07-15       Impact factor: 5.742

Review 8.  Tetraspanins as regulators of the tumour microenvironment: implications for metastasis and therapeutic strategies.

Authors:  S Detchokul; E D Williams; M W Parker; A G Frauman
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

9.  A novel therapeutic strategy with anti-CD9 antibody in gastric cancers.

Authors:  Taisei Nakamoto; Yoko Murayama; Kenji Oritani; Claude Boucheix; Eric Rubinstein; Makoto Nishida; Fumie Katsube; Kenji Watabe; Shinichi Kiso; Shusaku Tsutsui; Shinji Tamura; Yasuhisa Shinomura; Norio Hayashi
Journal:  J Gastroenterol       Date:  2009-05-26       Impact factor: 7.527

10.  CD 9 and vimentin distinguish clear cell from chromophobe renal cell carcinoma.

Authors:  Ariel A Williams; John P T Higgins; Hongjuan Zhao; Börje Ljunberg; James D Brooks
Journal:  BMC Clin Pathol       Date:  2009-11-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.